Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06739668 · ClinicalTrials.gov registry record · NA
Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction
A NA study of Cognitive Dysfunction and Post-Acute COVID-19 Syndrome, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06739668: Completed NA study of Cognitive Dysfunction and Post-Acute COVID-19 Syndrome, sponsored by Icahn School of Medicine at Mount Sinai.
NCT06739668 is a NA study of Cognitive Dysfunction and Post-Acute COVID-19 Syndrome that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 30 participants, below the 1,992-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06739668, a NA study of Cognitive Dysfunction and Post-Acute COVID-19 Syndrome, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical studies. A prospective randomized controlled study of 30 participants with PASC and moderate to severe cognitive dysfunction. Total study duration will be 8 weeks, including 4 weeks of treatment and 4 weeks of untreated follow up.
Primary Outcome
Feasibility of using the device at home will be measured based upon the proportion of successfully completed treatments.
Conditions Studied
Interventions
- DEVICE Sham Device
- DEVICE Pascal device
Study Locations (1)
New York
- The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2025-12-01 |
| Phase | NA |
What the finished NCT06739668 record still lists
NCT06739668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,992-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Cognitive Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Sham Device is the first listed.
NCT06739668 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06739668 about?
NCT06739668 is a clinical study titled "Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction". The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical studies. A prospective randomized controlled study of 30 participants with PAS...
What is the current status of trial NCT06739668?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2024-12-19. Estimated completion is 2025-12-01.
What conditions does trial NCT06739668 study?
This clinical trial studies the following conditions: Cognitive Dysfunction, Post-Acute COVID-19 Syndrome.
What interventions are being tested in trial NCT06739668?
The interventions under investigation include: Sham Device (DEVICE), Pascal device (DEVICE).
Who is sponsoring clinical trial NCT06739668?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06739668 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06739668's enrollment target sits among peer trials
30 31st of 45 higher than 13 of 45 other Cognitive Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
RECRUITING · NA
-
High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults With HIV
RECRUITING · NA
-
Long COVID Brain Fog: Cognitive Rehabilitation Trial
RECRUITING · NA
-
Up-2 Study: Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults
RECRUITING · NA
-
Strengthening Neuro-Cognitive Skills for Success in School, Work and Beyond
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI